I used AHA in PacBio's smrtanalysis-2.0.1 to scaffold contigs using long-read PacBio data. I now have the output files "scaffold.gml" and "scaffold.fasta". I now realise I have no idea how to use these files and my contigs to generate one long fasta sequence. Can anyone help me out here?
-
-
Hi schroedj,
The scaffold.fasta should contain the most contiguous sequence that the data and algorithm is able to generate. If it isn't "one long fasta sequence" then you need to look into why you're getting the results you are getting, or if AHA is making any difference. There should be very basic stats on the number of scaffolds created, which you can compare to the number of contigs you supplied. Is this what you are asking about?
We look at:
How large is the genome you are trying to assemble? (AHA is only supported up to 200Mb)
How "good" are the contigs going into the AHA? (number of contigs, contig lengths, %of genome, etc.)
How much PacBio Data are you supplying? (My personal rule-of thumb is to give AHA at least 5x coverage, but 2x coverage is the minimum to get any results at all. That is because the "redundancy" parameter is set to 2 by default. This is the minimum number of reads needed to link two contigs).
The parameters to tune AHA can be found in the smrtpipe reference guide:
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment